Abstract
Silkworm pupae protein is a good source of high quality protein. The hydrolyzates of silkworm pupae protein catalyzed by neutrase, pepsin, acidic protease (Asperqiius usamii NO. 537), flavourzyme, alcalase, and trypsin with inhibitory activity on angiotensin I-converting enzyme (ACE) were identified by HPLC. The hydrolyzates catalyzed by acidic protease exerted the highest inhibitory activity on ACE. The hydrolyzing conditions were optimized by one-factor, factional factorial (FFD), and center composite (CCD) design methods, and response surface methodology (RSM). Statistical analyses showed that regression of the second-order model equation is suitable to describe ACE inhibitory bioactivity. The predicted inhibitory activity of hydrolyzates on ACE was 73.5 % at a concentration of 2.0 mg/ml. Optimized RSM technique decreased IC50 of hydrolyzates inhibiting ACE to 1.4 mg/mL from 2.5mg/ml. The molecular weight of the components of the hydrolyzates with inhibitory activity on ACE varied from less than 500 to about 1000 Da by ultra-filter analysis. These studies suggest that hydrolyzates of silkworm protein contain ACE inhibitory activity that could form a potential source of ACE inhibitor drugs.
Keywords: Angiotensin converting enzyme, silkworm pupae protein, Bombyx mori, hypertension, hydrolyze
Current Pharmaceutical Biotechnology
Title: Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Volume: 9 Issue: 4
Author(s): Wei Wang, Shengrong Shen, Qihe Chen, Bo Tang, Guoqing He, Hui Ruan and Undurti N. Das
Affiliation:
Keywords: Angiotensin converting enzyme, silkworm pupae protein, Bombyx mori, hypertension, hydrolyze
Abstract: Silkworm pupae protein is a good source of high quality protein. The hydrolyzates of silkworm pupae protein catalyzed by neutrase, pepsin, acidic protease (Asperqiius usamii NO. 537), flavourzyme, alcalase, and trypsin with inhibitory activity on angiotensin I-converting enzyme (ACE) were identified by HPLC. The hydrolyzates catalyzed by acidic protease exerted the highest inhibitory activity on ACE. The hydrolyzing conditions were optimized by one-factor, factional factorial (FFD), and center composite (CCD) design methods, and response surface methodology (RSM). Statistical analyses showed that regression of the second-order model equation is suitable to describe ACE inhibitory bioactivity. The predicted inhibitory activity of hydrolyzates on ACE was 73.5 % at a concentration of 2.0 mg/ml. Optimized RSM technique decreased IC50 of hydrolyzates inhibiting ACE to 1.4 mg/mL from 2.5mg/ml. The molecular weight of the components of the hydrolyzates with inhibitory activity on ACE varied from less than 500 to about 1000 Da by ultra-filter analysis. These studies suggest that hydrolyzates of silkworm protein contain ACE inhibitory activity that could form a potential source of ACE inhibitor drugs.
Export Options
About this article
Cite this article as:
Wang Wei, Shen Shengrong, Chen Qihe, Tang Bo, He Guoqing, Ruan Hui and Das N. Undurti, Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP), Current Pharmaceutical Biotechnology 2008; 9 (4) . https://dx.doi.org/10.2174/138920108785161578
DOI https://dx.doi.org/10.2174/138920108785161578 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Adolescent Alcohol Abuse and Dependence: Development, Diagnosis, Treatment and Outcomes
Current Psychiatry Reviews Method Validation and Simultaneous Determination of Retinol, Retinyl Palmitate, β-Carotene, α-Tocopherol and Vitamin C in Rat Serum Treated with 7,12 Dimethylbenz[a]Anthracene and Plantago major L. by High- Performance Liquid Chromatography Using Diode-Array Detection
Combinatorial Chemistry & High Throughput Screening The Use of Propolis in Micro/Nanostructured Pharmaceutical Formulations
Recent Patents on Drug Delivery & Formulation Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Pharmacological Treatment of Hypoxic-Ischemic Reperfusion Injury of the Newborn Brain in the Clinical Setting: What are the Possibilities in the Near Future?
Current Pediatric Reviews Role of Perindopril in the Prevention of Stroke
Recent Patents on Cardiovascular Drug Discovery Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials The Effect of Acute Hypoxia on Excitability in the Heart and the L-Type Calcium Channel as a Therapeutic Target
Current Drug Discovery Technologies Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Adrenocortical Crisis Triggered by Levothyroxine in an Unrecognized Autoimmune Polyglandular Syndrome Type-2: A Case Report with Review of the Literature
Current Drug Safety The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Painful Peripheral Neuropathies
Current Neuropharmacology Retraction Notice: Prevention of Emetic Episodes During Cesarean Delivery Performed Under Regional Anesthesia in Parturients
Current Drug Safety Fibromyalgia
Current Rheumatology Reviews Renin Inhibition as a New Strategy to Combat Cardiovascular Disease
Current Hypertension Reviews Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology